Jean-Francois Korobelnik

Uczestniczy w 2 elementy

Elementy, w których Jean-Francois Korobelnik uczestniczy

piątek 20 czerwiec, 2025

Strefa czasowa: (GMT-05:00) Eastern Time (US & Canada)

12:10

A 96-week PULSAR Phase 3 trial post-hoc analysis: Rapid and sustained fluid control with aflibercept 8mg every 12 weeks or longer, as defined by fluid-free status at Weeks 16, 48, and 96 stratified by baseline CRT and BCVA - 5434

Vancouver Convention Centre (East Building) - Ballroom B

12:11 - 12:16 | 5 min.

Author’s Name(s): David Wong, Praveen Patel, Paolo Lanzetta, Jean-François Korobelnik, Sobha Sivaprasad, Sergio Leal, Tobias Machewitz, Xin ZhangAuthor’s Disclosure Block: David Wong: Alcon, Employment/honoraria/consulting fees, Abbviw, Employment/honoraria/consulting fees, Apellis, Employment/honoraria/consulting fees, Astellas, Employment/honoraria/consulting fees, Bayer, Grant/research support, Roche, Employment/honoraria/consulting fees, Zeiss, Emp...

12:15

Q&A

Vancouver Convention Centre (East Building) - Ballroom B

12:16 - 12:19 | 3 min.